These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36042521)

  • 41. Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma.
    Arai M; Nobusawa S; Ikota H; Takemura S; Nakazato Y
    Brain Tumor Pathol; 2012 Oct; 29(4):201-6. PubMed ID: 22323113
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
    Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
    Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Atypical cartilage in type II germ cell tumors of the mediastinum show significantly different patterns of IDH1/2 mutations from conventional chondrosarcoma.
    Warmke LM; Cheng L; Sperling RM; Sen JD; Ulbright TM
    Mod Pathol; 2022 Nov; 35(11):1636-1643. PubMed ID: 35660795
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients.
    Stancheva G; Goranova T; Laleva M; Kamenova M; Mitkova A; Velinov N; Poptodorov G; Mitev V; Kaneva R; Gabrovsky N
    Biomed Res Int; 2014; 2014():654727. PubMed ID: 24868540
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients.
    Aref S; Kamel Areida el S; Abdel Aaal MF; Adam OM; El-Ghonemy MS; El-Baiomy MA; Zeid TA
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):550-5. PubMed ID: 26189213
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?
    Petrova L; Vrbacky F; Lanska M; Zavrelova A; Zak P; Hrochova K
    Clin Biochem; 2018 Nov; 61():34-39. PubMed ID: 30176240
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.
    Patel KP; Ravandi F; Ma D; Paladugu A; Barkoh BA; Medeiros LJ; Luthra R
    Am J Clin Pathol; 2011 Jan; 135(1):35-45. PubMed ID: 21173122
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with
    Molenaar RJ; Coelen RJS; Khurshed M; Roos E; Caan MWA; van Linde ME; Kouwenhoven M; Bramer JAM; Bovée JVMG; Mathôt RA; Klümpen HJ; van Laarhoven HWM; van Noorden CJF; Vandertop WP; Gelderblom H; van Gulik TM; Wilmink JW
    BMJ Open; 2017 Jun; 7(6):e014961. PubMed ID: 28601826
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genomic Profiling of Low-grade Intramedullary Cartilage Tumors Can Distinguish Enchondroma From Chondrosarcoma.
    Joseph NM; McGill KC; Horvai AE
    Am J Surg Pathol; 2021 Jun; 45(6):812-819. PubMed ID: 33239505
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.
    Peterse EFP; van den Akker BEWM; Niessen B; Oosting J; Suijker J; de Jong Y; Danen EHJ; Cleton-Jansen AM; Bovée JVMG
    Mol Cancer Res; 2017 Dec; 15(12):1714-1721. PubMed ID: 28860121
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype.
    Cleven AH; Zwartkruis E; Hogendoorn PC; Kroon HM; Briaire-de Bruijn I; Bovée JV
    Histopathology; 2015 Oct; 67(4):483-90. PubMed ID: 25648524
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
    Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
    Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
    Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
    J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.
    Yamaguchi S; Iwanaga E; Tokunaga K; Nanri T; Shimomura T; Suzushima H; Mitsuya H; Asou N
    Eur J Haematol; 2014 Jun; 92(6):471-7. PubMed ID: 24443894
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Isocitrate Dehydrogenase
    Murugan AK; Alzahrani AS
    Br J Biomed Sci; 2022; 79():10208. PubMed ID: 35996504
    [No Abstract]   [Full Text] [Related]  

  • 56. Plk1 regulates mutant IDH1 enzyme activity and mutant IDH2 ubiquitination in mitosis.
    Saikiran Reddy M; Bhattacharjee D; Jain N
    Cell Signal; 2022 Apr; 92():110279. PubMed ID: 35143931
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.
    Zou P; Xu H; Chen P; Yan Q; Zhao L; Zhao P; Gu A
    PLoS One; 2013; 8(7):e68782. PubMed ID: 23894344
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Integrating Morphology and Genetics in the Diagnosis of Cartilage Tumors.
    de Andrea CE; San-Julian M; Bovée JVMG
    Surg Pathol Clin; 2017 Sep; 10(3):537-552. PubMed ID: 28797501
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting.
    Ibáñez M; Such E; Cervera J; Luna I; Gómez-Seguí I; López-Pavía M; Dolz S; Barragán E; Fuster O; Llop M; Rodríguez-Veiga R; Avaria A; Oltra S; Senent ML; Moscardó F; Montesinos P; Martínez-Cuadrón D; Martín G; Sanz MA
    J Mol Diagn; 2012 Nov; 14(6):594-601. PubMed ID: 22929312
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection.
    Gutteridge A; Rathbone VM; Gibbons R; Bi M; Archard N; Davies KEJ; Brown J; Plagnol V; Pillay N; Amary F; O'Donnell P; Gupta M; Tirabosco R; Flanagan AM; Forshew T
    Cancer Med; 2017 Oct; 6(10):2194-2202. PubMed ID: 28834325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.